title: Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
authors.forename: U
authors.initials: U
authors.lastname: Burkhard-Meier
authors.forename: D
authors.initials: D
authors.lastname: Söhngen
authors.forename: H P
authors.initials: HP
authors.lastname: Schultheiss
authors.forename: A
authors.initials: A
authors.lastname: Greinacher
authors.forename: B
authors.initials: B
authors.lastname: Schwartzkopff
authors.forename: M
authors.initials: M
authors.lastname: Vogt
authors.forename: A
authors.initials: A
authors.lastname: Heyll
authors.forename: W
authors.initials: W
authors.lastname: Schneider
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004617:Embolism / Q000517:prevention & control*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid